Chemical Communications · 2018 · 38 citations · 32 references
Life SciencesBiochemistryMedicinal ChemistryDementiaNeurodegenerationProtein BiochemistryAlzheimer DiseaseAmyloid FormationPeptide ChemistryProtein AggregationProtein Aggregation DisordersProtein ConformationAmyloid Beta AggregationAmyloid Beta PeptidesAmyloid InhibitionMembrane PerturbationProtein Aggregation InhibitorsTau AggregationTau Protein AggregationTau Toxicity
Aggregation and accumulation of amyloid β and tau proteins to plaques and neurofibrillary tangles are the key pathogenic events in Alzheimer's disease. Here, we studied the capability of the cyclic d,l-α-peptide CP-2 as a conformational inhibitor of different amyloids to cross-interact with tau-derived AcPHF6 peptide and inhibit its aggregation, membrane perturbation and toxicity.
32
Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis
Rakez Kayed, Elizabeth Head, Jennifer L. Thompson et al. · Science · 2003 · 4.1K citations
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Jeff Sevigny, Ping Chiao, Thierry Bussière et al. · Nature · 2016 · 3.1K citations
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
Monica Bucciantini, Elisa Giannoni, Fabrizio Chiti et al. · Nature · 2002 · 2.4K citations
Self-assembling organic nanotubes based on a cyclic peptide architecture
M. Reza Ghadiri, Juan R. Granja, Ronald A. Milligan et al. · Nature · 1993 · 1.7K citations
Natural Sciences, Materials Engineering, Materials Science +14